2020
Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
Perrone E, Manara P, Lopez S, Bellone S, Bonazzoli E, Manzano A, Zammataro L, Bianchi A, Zeybek B, Buza N, Tymon‐Rosario J, Altwerger G, Han C, Menderes G, Huang GS, Ratner E, Silasi D, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD. Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. Molecular Oncology 2020, 14: 645-656. PMID: 31891442, PMCID: PMC7053235, DOI: 10.1002/1878-0261.12627.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, Monoclonal, HumanizedAntibody-Dependent Cell CytotoxicityAntigens, NeoplasmAntineoplastic AgentsCamptothecinCarcinoma, EndometrioidCell Adhesion MoleculesCell DifferentiationCell Line, TumorCell SurvivalEndometrial NeoplasmsFemaleHumansImmunoconjugatesImmunohistochemistryIrinotecanMiceMice, SCIDTissue Array AnalysisXenograft Model Antitumor AssaysConceptsAntibody-dependent cell cytotoxicityCell surface antigen 2EC cell linesSacituzumab govitecanTrop-2 expressionPrimary tumor cell linesTrop-2Xenograft modelAntigen 2Cell linesTumor cell linesCommon gynecologic malignancyFuture clinical trialsChromium release assaysParaffin-embedded tumorsTumor growth inhibitionSignificant bystander killingEC xenograftsGynecologic malignanciesEndometrial cancerEndometrial adenocarcinomaEndometrioid carcinoma tissuesPreclinical activityControl antibodyClinical trials
2018
Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer
Albright BB, Black JD, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Buza N, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer. Gynecologic Oncology Reports 2018, 23: 28-33. PMID: 29387776, PMCID: PMC5771964, DOI: 10.1016/j.gore.2018.01.003.Peer-Reviewed Original ResearchLaparoscopic/robotic approachType II endometrial adenocarcinomaRisk of recurrenceDisease recurrenceFinal pathologyEndometrial adenocarcinomaFallopian tubeTumor fragmentsType II endometrial cancerRobotic approachCox proportional hazards modelHigher stage diseaseSingle institution experienceIndependent prognostic impactType IProportional hazards modelResult of traumaElectronic medical recordsCharacteristics of casesBaseline characteristicsExtensive diseaseLymphovascular invasionOverall survivalPatient comorbiditiesStage disease
2017
Comprehensive Analysis of PAX8 Expression in Epithelial Malignancies of the Uterine Cervix
Wong S, Hong W, Hui P, Buza N. Comprehensive Analysis of PAX8 Expression in Epithelial Malignancies of the Uterine Cervix. International Journal Of Gynecological Pathology 2017, 36: 101-106. PMID: 27362905, DOI: 10.1097/pgp.0000000000000309.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaEpithelial malignanciesPAX8 expressionAdenosquamous carcinomaMajority of SCCsCervical squamous cell carcinomaPossible primary sitesEndometrioid-type tumorsWeak nuclear stainingTissue microarray slidesGynecologic malignanciesEndometrial adenocarcinomaEndometrioid adenocarcinomaMetastatic lesionsEndometrial carcinomaMetastatic sitesUterine cervixCell carcinomaCervical tumorsEndocervical adenocarcinomaDifferential diagnosisPrimary siteAdenocarcinomaCarcinomaMalignancy
2015
Diagnostic application of KRAS mutation testing in uterine microglandular proliferations
Hong W, Abi-Raad R, Alomari AK, Hui P, Buza N. Diagnostic application of KRAS mutation testing in uterine microglandular proliferations. Human Pathology 2015, 46: 1000-1005. PMID: 25997988, DOI: 10.1016/j.humpath.2015.03.010.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overBiopsyCell ProliferationCervix UteriDiagnosis, DifferentialDNA Mutational AnalysisEndometrial HyperplasiaEndometrial NeoplasmsFemaleHumansMiddle AgedMutationPredictive Value of TestsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsConceptsKRAS mutation analysisEndometrial adenocarcinomaMicroglandular hyperplasiaMicroglandular patternKRAS mutationsCareful morphological assessmentEndometrial mucinous carcinomaKRAS mutation testingCases of EMAMutation analysisFrequent KRAS mutationsElectronic medical recordsDifferential diagnostic toolHigh mitotic activityEndometrial biopsyImmunohistochemical workupUterine cervixMucinous carcinomaClinical historyDiagnostic challengeDiagnostic dilemmaGlandular proliferationMucinous lesionsMedical recordsEAC cases
2014
Mitotically Active Microglandular Hyperplasia of the Cervix
Abi-Raad R, Alomari A, Hui P, Buza N. Mitotically Active Microglandular Hyperplasia of the Cervix. International Journal Of Gynecological Pathology 2014, 33: 524-530. PMID: 25083971, DOI: 10.1097/pgp.0000000000000086.Peer-Reviewed Original ResearchConceptsHuman papillomavirus (HPV) statusMicroglandular hyperplasiaSmall biopsy specimensEndometrial malignancyClinical historyBiopsy specimensHigh risk human papillomavirus statusCarcinoembryonic antigenKi-67 proliferation indexMitotic activityModerate nuclear atypiaPatient's clinical historySignet ring cellsSignificant mitotic activityReticular growth patternMicroglandular patternVimentin immunostainsPatient ageCase seriesEndocervical polypEndometrial adenocarcinomaEndocervical glandsDiagnostic dilemmaClinical prognosisMucinous differentiation
2013
Cancerous ‘floater’: a lesson learned about tissue identity testing, endometrial cancer and microsatellite instability
Bossuyt V, Buza N, Ngo NT, Much MA, Asis MC, Schwartz PE, Hui P. Cancerous ‘floater’: a lesson learned about tissue identity testing, endometrial cancer and microsatellite instability. Modern Pathology 2013, 26: 1264-1269. PMID: 23558568, DOI: 10.1038/modpathol.2013.63.Peer-Reviewed Original ResearchConceptsEndometrial curettageBackground endometriumStaging surgeryEndometrial cancerEndometrial polypsEndometrioid adenocarcinomaEndometrial adenocarcinomaFurther workupPap smearSecretory endometriumDiagnostic workupEndometrial cellsDNA genotypingAdenocarcinoma tissuesMolecular testingMicrosatellite instabilityAllelic patternsAdenocarcinomaPatientsConfirmation of contaminationTissue fragmentsCurettageEndometriumWorkupMolecular pathologists
2010
Postoperative Vaginal Cuff Brachytherapy Alone (VB) Provides Equally Effective Treatment with Less Toxicity Than External Beam Radiation and Vaginal Cuff Brachytherapy (EXT + VB) in the Treatment of Stage II Endometrial Adenocarcinoma
Galper S, Harrington J, Ratner E, Deng Y, Zelterman D, Hui P, Rutherford T, Higgins S. Postoperative Vaginal Cuff Brachytherapy Alone (VB) Provides Equally Effective Treatment with Less Toxicity Than External Beam Radiation and Vaginal Cuff Brachytherapy (EXT + VB) in the Treatment of Stage II Endometrial Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s415-s416. DOI: 10.1016/j.ijrobp.2010.07.978.Peer-Reviewed Original ResearchExpression of glypican 3 in placental site trophoblastic tumor
Ou-Yang RJ, Hui P, Yang XJ, Zynger DL. Expression of glypican 3 in placental site trophoblastic tumor. Diagnostic Pathology 2010, 5: 64. PMID: 20868507, PMCID: PMC2954974, DOI: 10.1186/1746-1596-5-64.Peer-Reviewed Original ResearchConceptsPlacental site trophoblastic tumorPlacental site noduleInvasive cervical squamous cell carcinomaCervical squamous cell carcinomaNon-trophoblastic tumorsSquamous cell carcinomaTrophoblastic tumorCell carcinomaCytoplasmic stainingRare gestational trophoblastic neoplasmDiagnostic markerGestational trophoblastic neoplasmsGestational trophoblastic diseaseUseful diagnostic markerNon-neoplastic tissuesMembrane-bound heparan sulfate proteoglycanEndometrial adenocarcinomaUterine tumorsIntermediate trophoblastTrophoblastic diseaseTrophoblastic neoplasmsImmunohistochemical expressionHepatocellular carcinomaImmunohistochemical markersResultsEighty percent